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1. Introduction 
Prosthetic joints improve the quality of life, but they may fail, necessitating revision or 
resection arthroplasty. The numbers of primary total hip and total knee arthroplasties have 
been increasing over the past decade, with nearly 800,000 such procedures performed in the 
United States in 2006 (Fig.1A)[1],with numbers projected to rise to 572,000 by 2030 and are 
expected to undergo a continuing rise, especially in light of an aging population[2]. 
Procedures to replace the shoulder, elbow, wrist, ankle, temporomandibular, 
metacarpophalangeal and interphalangeal joints are less commonly performed. The growth 
in the number of prosthetic joint replacement procedures provides new opportunities for 
infections to take hold.  
The classification of the arthroplasty associated infection may distinguishes two major 
types―septic arthritis and osteomyelitis, which both involve the inflammatory 
destruction of joint and bone. The incidence of septic arthritis is between 2 and 10 in 
100,000 in the general populace but may be as high as 30–70 per 100,000 in rheumatoid 
arthritis sufferers or recipients of prosthetic joints [3-5] and is more common in children 
than adults, and in males rather than females [6]. Haematogenous osteomyelitis most 
frequently effects children and the elderly [7]. In children, the incidence is typically 
between 1 in 5000 and 1 in 10,000 [8]. It has been argued that the incidence of 
haematogenous osteomyelitis is decreasing with an annual fall in childhood cases of 0.185 
per 100,000 people recorded in Glasgow, Scotland between 1970 and 1997 [8-10]. 
Conversely, osteomyelitis resulting from direct infection is reportedly on the 
increase[10,11]. Local spread of infection from contiguous tissue to bone or direct 
infection can occur at any age, with foreign body implants a substantial risk factor [7]. 
Infection, although uncommon, is the most serious complication, occurring in 0.8 to 1.9% of 
knee arthroplasties[12-14] and 0.3 to 1.7% of hip arthroplasties[14-16]. The frequency of 
infection is increasing as the number of primary arthroplasties increases (Fig. 1B)[17]. These 
infections are increasingly difficult to treat with the rise in antibiotic-resistant forms. 
2. Risk factors for infection 
Patient-related risk factors for infection include previous revision arthroplasty or previous 
infection associated with a prosthetic joint at the same site, tobacco abuse, obesity, 
rheumatoid arthritis, a neoplasm, immunosuppression, and diabetes mellitus.  
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Surgical risk factors include simultaneous bilateral arthroplasty, a long operative time(>2.5 
hours), and allogeneic blood transfusion. 
Postoperative risk factors include woundhealing complications (e.g., superficial infection, 
hematoma, delayed healing, wound necrosis, and dehiscence), atrial fibrillation, myocardial 
infarction, urinary tract infection, prolonged hospital stay, and S. aureus bacteremia[12-
15],[18-21]. 
 
 
Fig. 1. Total Arthroplasties Performed and Prosthetic Infections, According to Procedure. 
Panel A shows the number of total arthroplasties performed from 1990 through 2006. Data 
are from the Centers for Disease Control and Prevention. Panel B shows the number of 
prosthetic joint infections from 1990 through 2004. Data are from Kurtz et al. 
An increased rate of infection occurs in the pre-damaged joint and is also associated with 
particular predispositions of the patients (Table 1) [22-24]. In articular, a joint prosthesis is a 
high risk predisposition for an infection. Perioperatively the initial bacterial entry into the 
joints may occur. On the other hand the implanted foreign material causes in addition to the 
severe joint disease present an additional reduction in local resistance, which facilitates 
haematogenous infections. The prosthetic materials are also additional binding sites for 
various bacteria, and act as a starting point for prosthetic infections. Thus, in addition to the 
local conditions, the bacterial properties and their specific pathogenity have to be 
considered for understanding the whole mechanism of infection. Basically, a too late or not  
 
 
Table 1. Predisposing factors 
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sufficiently cured joint infection can cause trophic and functional limitations or can even be 
the starting point of a progressive infection spreading in continuity, lymphogenic or 
haematogenic. In general, the detection and treatment of acute infectious arthritis is an acute 
emerging situation, in which a delay may progress to further septic inflammation[23]. 
3. Classification of the arthroplasty associated infection  
The arthroplasty associated infection may distinguishes two major types―septic arthritis 
and osteomyelitis, which both cause serious morbidity and are often difficult to manage.  
Septic arthritis is a joint disease typified by bacterial colonisation and rapid articular 
destruction[6]. Infiltration and growth of bacteria within the synovium results in 
inflammation with infiltration of leukocytes into the joint fluid [4]. The production of 
reactive oxygen species and host matrix metalloproteinases (MMPs), lysosomal enzymes 
and bacterial toxins contribute to the destruction of cartilage. This starts with degradation of 
host proteoglycans followed by collagen breakdown within hours of infection, and is 
mediated by polymorphonuclear leukocytes[3-5,24]. The containment of the inflammatory 
process within the joint results in increasing pressure, which impedes blood and nutrient 
supply to the joint exacerbating joint damage and facilitating destruction of cartilage and the 
synovium. Permanent destruction of articular cartilage and subchondral bone can occur 
rapidly, within just a few days[24]. 
Osteomyelitis describes a range of infections in which bone is colonized with 
microorganisms, with associated inflammation and bone destruction. Acute osteomyelitic 
foci are characterized by pus-forming inflammation at the site of microbial colonisation. 
Damage to bone matrix and compression and destruction of vasculature is also observed as 
the infection spreads to surrounding soft tissues, which can further exacerbate bone 
necrosis[7,10].Sections of dead bone, known as sequestra, can form which may then detach 
to form separate infectious foci which, due to the lack of vasculature, are protected from 
immune cells and antibiotics[7,10]. Such areas of dead, infected tissues that are inaccessible 
to antimicrobials or the immune response can lead to chronic persistence of the 
infection[10]. 
The principal routes of these infection involve: (I) haematogenous or lymphogenous seed of 
the pathogen, (II) contiguous, by contact with a neighboring infected site, (III) or direct, 
resulting from infiltration of bone, often following inj ury, surgery or implantation of a 
foreign body, such as joint repalcement[25]. The range of environments experienced by the 
bacterium differs for each route and hence the virulence factors that are involved in 
pathology may be different for each route of infection. 
Another classification of arthroplasty associated infection distinguishes acute, chronic and 
reactive forms, which differ in their type of joint infection and their triggering bacteria. 
Infection with virulent organisms (e.g., S. aureus and gram-negative bacilli) inoculated at 
implantation is typically manifested as acute infection in the first 3 months (or, with 
hematogenous seeding of the implant, at any time) after surgery, whereas infection with less 
virulent organisms (e.g., coagulase-negative staphylococci and P. acnes) is more often 
manifested as chronic infection several months (or years) postoperatively. The most 
common symptom of infection associated with a prosthetic joint is pain. In acute infection, 
local signs and symptoms (e.g., severe pain, swelling, erythema, and warmth at the infected 
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joint) and fever are common. Chronic infection generally has a more subtle presentation, 
with pain alone, and it is often accompanied by loosening of the prosthesis at the bone–
cement interface and sometimes by sinus tract formation with discharge.  
Reactive arthritis is a postinfectious complication with no need of presence for viable 
pathogens in the joint. While reactive arthritis often simultaneously affect several joints, the 
presence of polyarthritic types of non reactive arthritis occur infrequently and then mostly 
as a result of several bacteriaemic phases. 
Among joint infections, the knee is the most frequent localization than others. Infection 
occurs in 0.8 to 1.9% of knee arthroplasties[12-14]and 0.3 to 1.7% of hip arthroplasties[14-16]. 
However, hip joint infections are aggravated by the fact that they can exist over a long time 
with only poor symptoms. Basically, there are no differences in the bacterial spectrum 
among large joints.  
4. Bacteria responsible for arthroplasty associated infection 
A broad range of bacterial species have been isolated in cases of septic arthritis and 
osteomyelitis[26]. Pathogens cultured from septic joints include S. aureus, Streptococcus 
pyogenes, Streptococcus pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Serratia 
marcescens, as well as Salmonella, Neisseria, Aerobacter, and Bacteroides species[4,24]. 
Staphylococcus and Streptococcus spp., Haemophilusinfluenzae, E. coli, P. aeruginosa, 
Salmonella and Mycobacterium spp. are all potential causes of osteomyelitis[7,10,27].  
 
 
Fig. 2. Causes of Infection Associated with Prosthetic Joints 
A small number of often otherwise nonvirulent bacteria contaminate the implant during 
surgery and persist as a biofilm despite a functional immune system and antimicrobial 
treatment. Commonly isolated microorganisms are shown. Unusual organisms that can also 
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cause infection include (but are not limited to) Actinomyces israelii, Aspergillus fumigatus, 
Histoplasma capsulatum, Sporothrix schenckii, Mycoplasma hominis, Tropheryma 
whipplei, and mycobacterium (including tuberculosis), brucella, candida, corynebacterium, 
granulicatella, and abiotrophia species. 
Some bacteria have preferences for certain infection routes and patterns. Infections not 
related to injuries or medical interventions (e.g. intraarticular puncture, joint replacement) 
are mostly resulting from often physiologic bacteriaemic periods.  
S. aureus is the most commonly identified pathogen both in septic arthritis and 
osteomyelitis, by a substantial margin, regardless of type or route of infection [3,7,28]. 
Staphylococci (S. aureus and coagulase-negative staphylococcus species) account for more 
than half of cases of prosthetic-hip and prosthetic-knee infection[29](Fig. 2). Other bacteria  
 
 
Table 2. Bacteria responsible for (hip) joint infections 
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and fungi cause the remainder of cases[30,31]. Moreover, Staphylococcus aureus has the 
dominance in acute septic arthritis, and is particularly common in patients with rheumatoid 
arthritis[32]while coagulase -negative staphylococci can be found mainly in periprosthetic 
infections and after diagnostic arthroscopies. 
 Other gram-positive bacteria as causative agents for hip joint infections are streptococci, 
especially Streptococcus pyogenes, Enterococcus faecalis and Corynebacteria species. 
Propionibacterium acnes is a common cause of infection associated with shoulder 
arthroplasty[33]. 
A large number of different gram-negative rods act as infectious agents on joints. The group 
of enterobacteria contains a broad spectrum of pathogens. Salmonella enterica, Shigella 
species, and Yersinia species are classically described as pathogens for purulent and reactive 
forms of arthritis. Pseudomonas aeruginosa can be found more often in predisposed 
patients (e.g. diabetics). In otherwise healthy people it is associated with iatrogenic modes of 
infection during diagnostic procedures.  
Campylobacter species, however, are classic agents of reactive arthritis, as well as the 
obligate intracellular bacteria Chlamydia trachomatis, Mycoplasma pneumoniae, and 
Ureaplasma urealyticum. From the spirochaetales only Borrelia burgdorferi sensu lato is 
relevant. Less commonly identified organisms for joint infections often accompanied with 
osteitis or osteomyelitis are Brucella species and Mycobacterium tuberculosis.  
Up to 20% of cases are polymicrobial, most commonly involving methicillin -resistant S. 
aureus (MRSA) or anaerobes, such as Bacteroides fragilis[34]. Approximately 7% of cases are 
culture-negative, often in the context of previous antimicrobial therapy[35]. 
An overview is shown in Table 2[8]. 
Infection with virulent organisms (e.g., S. aureus and gram-negative bacilli) inoculated at 
implantation is typically manifested as acute infection in the first 3 months (or, with 
hematogenous seeding of the implant, at any time) after surgery, whereas infection with less 
virulent organisms (e.g., coagulase-negative staphylococci and P. acnes) is more often 
manifested as chronic infection several months (or years) postoperatively. 
5. Interaction of staphylococci with bone 
5.1 Genomic features of staphylococci associated with bone infections 
A number of studies have attempted to identify an association between the possession of 
certain virulence genes by Staphylococci and invasive disease. Thus Peacock et 
al.[36]suggested that the possession of certain combinations of virulence factor genes is 
associated with invasive disease, and increased severity of infection following examination 
of a panel of 334 S. aureus isolates by PCR. The isolates comprised those from 179 healthy 
patients, 94 hospitalacquired isolates and 61 community-acquired isolates. Seven putative 
virulence genes, including the adhesin genes fnbA and cna, the toxin genes sej, eta and hlg, 
and icaA, which is involved in biofilm production, were found to be associated with 
invasive isolates. The association with specific types of invasive infection was not examined 
and indeed the small number of isolates examined in this study would have precluded such 
an analysis.  
The genes for the fibronectin-binding proteins fnbA and fnbB have been reported to be 
present in 98% and 99% of clinical isolates, respectively, from a range of orthopaedic 
associated infections, whereas the cna gene, encoding the collagen -binding protein was 
identified in just 46% of isolates[37]. Another study by Peacock et al.[38]found the 
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prevalence of both fnbA and fnbB genes, as opposed to just one of the two, to be 
significantly higher in invasive isolates than in ‘carriage’ strains in a panel of 163 strains, 
which included septic arthritis and osteomyelitis isolates. Genes encoding Panton-Valentine 
leukocidin were found to be present in 59 of 89 S. aureus isolates from cases of acute 
haematogenous osteomyelitis. The presence of pvl genes is associated with an increased risk 
of severe infection requiring intensive care, bacteremia and more severe systemic 
inflammation [39,40]. However, one of the problems with the above studies is that it is 
unclear how representative these strain collections are of those isolates carried in other 
establishments and regions across the world, since strain typing was not reported. 
Strain typing studies of S. aureus, using multilocus sequence typing (MLST) and 
comparative genomic microarray hybridizations have so far failed to identify any specific 
clonal lineages associated with invasive disease. However, these studies did not use a 
collection of isolates from specific invasive diseases and therefore do not rule out the 
possibility that specific lineages or genes are associated with specific types of infection, such 
as osteomyelitis or septic arthritis.  
To date, the only genome comparison study relevant to S. aureus bone infections has been 
done using comparative genome microarray hybridisations of the S. aureus UAMS-1 strain, 
isolated from an osteomyelitis patient, with a range of genome sequenced strains[41]. These 
authors found variations in the complement of adhesin, toxin, exoenzyme and regulatory 
genes. Although it is not possible to draw general conclusions about association with bone 
infection from characterisation of a single strain, the presence of fnbA, but not fnbB or the 
bone sialoprotein-binding gene bbp, in UAMS-1 suggest that fnbB and bbp are dispensable 
for bone infection, at least in certain genetic backgrounds. Thus at this juncture there is a 
lack of evidence to support or disprove an association between specific S. aureus lineages or 
specific genomic features and the pathogenesis of bone infections. 
5.2 Bone as a target organ 
In terrestrial vertebrates mature bone is made up of dense surface plates of bone, known as 
the cortices, and within these is a network of bone struts oriented to oppose loading forces, 
known as trabecular bone. Trabecular bone is typically replaced every 3–4 years, with the 
denser cortical bone taking over a decade to replace in adults. This process of continual 
remodelling is required to remove old bone and microfractures to ensure bone integrity and 
mineral homeostasis. The skeleton is a dynamic organ system, in a state of perpetual 
turnover which is continually remodelled by the actions of two cell types, osteoblasts and 
osteoclasts.  
Osteoblasts are responsible for the deposition of bone matrix; they are found on bone 
surfaces and are derived from mesenchymal steoprogenitor cells. These cells secrete osteoid, 
a mixture of bone matrix proteins primarily made up of type I collagen (over 90%), 
proteoglycans such as decorin and biglycan, glycoproteins such as fibronectin, osteonectin 
and tenascin-C, osteopontin, osteocalcin and bone sialoprotein, oriented along stress lines. 
Osteoblasts are also thought to facilitate the mineralization of bone matrix, whereby 
hydroxyapatite, [Ca3(PO4)2]3·Ca[OH]2, crystals form, making up around 90% of bone 
matrix. It is thought that ‘nucleators’ are required to instigate mineralisation, and 
phosphate-containing matrix proteins like bone sialoprotein and osteopontin are likely to 
play such a role. Osteoblasts also produce tissue nonspecific alkaline phosphatase (TNAP) 
which cleaves phosphate esters to liberate free inorganic phosphate, which is key to the 
process of mineralisation[42]. 
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Osteoblasts are not terminally differentiated, and some may form osteocytes and become 
implanted in the bone matrix, eventually ceasing the secretion of osteoid, whilst others 
undergo apoptosis. Osteocytes are also involved in bone maintenance, detecting stress 
within the bone through echanosensitive mechanisms located in extensive cellular 
projections, called canaliculi, that interconnect osteocytes[42]. Osteocytes are thought to 
respond to mechanical stress by undergoing apoptosis, leading to osteoclast recruitment and 
differentiation, possibly by alterations in the levels of soluble factors produced by the 
osteocyte. Candidates include transforming growth factor ͊(TGF-͊), which may suppress 
osteoclastogenesis when produced by healthy osteocytes[43,44]. 
Osteoclasts, which are multinucleate cells derived from the acrophage-monocyte lineage, 
perform the opposing action of bone matrix removal. These cells express large quantities of 
a vacuolar-type H+-ATPase on their cell surface, along with chloride channel 7 (ClC 
7)enabling localised hydrochloric acid secretion into a closed compartment, known as the 
resorption lacuna, and subsequent olubilisation of bone mineral. The cell is attached to the 
bone matrix by a sealing zone membrane to create this compartment, and fusion of acidified 
vesicles with the plasma membrane contributes further to acid release[45].Following mineral 
solubilisation, proteolysis of bone matrix proteins is then possible. Cathepsin K is centrally 
involved in degradation of bone matrix, it is highly expressed by osteoclasts and digests 
substrates such as collagen and osteonectin. Evidence from knock-out mouse and selective 
inhibitor experiments indicates that cathepsin L, and MMPs also play a role in degrading 
bone matrix[46]. Osteoclasts also secrete acid phosphatases, such as tartrate-resistant acid 
phosphatase(TRAcP), which is used as an osteoclast marker and is activated by cathepsin K 
cleavage. TRAcP is able to generate reactive oxygen species in addition to having 
phosphatase activity. The exact cellular function of TRAcP in bone resorption is not well 
understood, but serum TRAcP levels correlate with bone-resorptive activity, and TRAcP-
deficient mice exhibit reduced osteoclastic bone resorption and increased bone 
mineralization. 
The balance of activity between these two cell types is crucial to maintaining the proper 
homeostasis of bone turnover, and any shift in the relative levels of osteoblast and osteoclast 
activity can result in bone pathology. Infection with a pathogen such as S. aureus is capable 
of stimulating such a shift, mediated in part by induction of an inflammatory response. 
There is intimate interaction between the two cell types, with osteoblasts interpreting the 
majority of extracellular signals and subsequently modulating osteoclast differentiation and 
function[44]. 
Interaction between the RANK (receptor activator for nuclear factor κB) receptor, expressed 
by osteoclast precursors, and its cognate ligand, RANKL, expressed by osteoblasts is 
essential for osteoclastogenesis [44]. RANKL is a homotrimeric protein displayed on the 
membrane of osteoblasts, although it may be secreted following cleavage by MMPs 7 or 14, 
or ADAM (a disintegrin and metalloprotease domain). Suppression of MMP 14-mediated 
secretion enhances osteoclastogenesis[47,48]. The RANK receptor is a homotrimeric 
transmembrane protein belonging to the tumour necrosis factor (TNF) receptor superfamily. 
Following binding of RANKL to RANK, TRAF (TNF receptor-associated factor) adaptor 
proteins are recruited, with binding sites for TRAF2, TRAF5 and TRAF6 all present on 
RANK. TRAF6 seems to play a central role in RANK mediated osteoclast formation, and 
mice deficient in TRAF6 are osteopetrotic whereas TRAF2 and TRAF5 are relatively 
marginal players in osteoclastogenesis. Signalling via RANK, and these adaptor proteins, 
activates a number of transcription factors, including NFκB (nuclear factor κB), AP-
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1(activator protein 1) and NFATc1 (nuclear factor of activated T-cells, cytoplasmic, 
calcineurin dependent 1) which drive osteoclast differentiation[44]. Osteoprotegrin (OPG) is 
an endogenous inhibitor of RANKL signalling, functioning as a decoy receptor that binds to 
RANKL and prevents its association with RANK. 
5.3 Inflammation in bone infection 
A number of host cytokines play a significant role in the pathogenesis of osteomyelitis, and 
there is strong evidence that production of these cytokines is induced by staphylococcal 
infection of bone, and that they directly contribute to bone destruction. In particular, the 
inflammatory cytokines tumour necrosis factor ǂ (TNFǂ), interleukin 1 (IL-1) and IL-6 seem 
to be especially important in bone physiology and pathology. In patients with acute 
osteomyelitis, plasma levels of TNFǂ, IL-1ǃ (the secreted form of IL-1) and IL-6 are all 
elevated. High levels of IL-1ǃ, IL-6 and TNFǂ are also found in the synovial fluid of patients 
with septic arthritis. Interestingly, specific polymorphisms in the IL-1ǂ and IL-6 genes have 
recently been found to be associated with an increased risk of osteomyelitis in the Greek 
population[49]. The most recently identified member of the IL-1 cytokine superfamily is IL-
33, has been shown to expressed in differentiated osteoblasts and blocks osteoclast 
formation from bone marrow precursor cells[50].  
A number of animal models of S. aureus osteomyelitis reveal that bone infection can lead to 
elevated levels of these cytokines both locally and systemically. Increased levels of IL-1ǃ 
have been measured in the tibiae of 22-month-old rats experimentally implanted with S. 
aureus infected needles, and the same animals have increased circulating levels of IL-6[51]. 
In a murine osteomyelitis model, bone levels of IL-1ǃ and IL-6 are significantly increased in 
the early post-infection period, with TNFǂ rising later during the infection. The local source 
of these cytokines is not fully clear. Production of IL-1ǃ can be induced in human osteoblast-
like cell lines by a variety of stimuli, including TNFǂ. However, infection of primary mouse 
osteoblasts with S.aureus results in increased transcription, but not increased protein 
synthesis or secretion of IL-1ǃ. TNFǂ is detectable only at low levels in human osteoblasts 
derived from mesenchymal stem cells and the osteosarcoma cell line MG63.Infiltrating 
immune cells may therefore be a more likely source of IL-1ǃ and TNFǂ in bone in response 
to infection. IL-6 however, is produced by osteoblasts in response to a variety of signals, 
including infection with S. aureus . 
These cytokines have potent effects on the process of bone remodelling, and are strongly 
implicated in the pathology of osteomyelitis. Cell culture models support the view that IL-1 
and TNFǂ stimulate the proliferation and differentiation of osteoclast progenitors into 
mature osteoclasts in the presence of osteoblasts. TNFǂ and IL-1ǃ also stimulate osteoclast-
mediated bone resorption, a process which may also require the presence of osteoblasts. 
Similarly, IL-6 increases bone resorption activity and osteoclast number in cultured mouse 
calvariae, and stimulates osteoclast differentiation in the presence of osteoblasts. In vivo, 
local administration of IL-1 and TNF antagonists in a non-human primate model of 
periodontitis results in significant reduction of osteoclast formation and bone destruction. 
Intravenous administration of TNFǂ and IL-1 in mice stimulates bone resorption in a dose-
dependent fashion, and deletion of the murine IL-1R, TNF-R1 and TNF-R2 receptors and of 
caspase-1 significantly decreases osteoclast number and the area of bone resorption in 
calvariae following lipopolysaccharide (LPS) injection. 
IL-1ǃ and TNFǂ also inhibit the differentiation of mesenchymal stem cells into osteoblast-
like cells, and suppress the accompanying mineralisation and increased expression of 
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alkaline phosphatase and procollagen I genes, although only TNFǂ inhibits osteonectin and 
osteopontin gene expression[52]. TNFǂ also decreases production of type I collagen and 
osteocalcin, and of alkaline phosphatase in a variety of osteoblast cell culture and bone 
tissue explant models, thereby reducing matrix deposition and mineralisation. 
Surface-associated material (SAM) from S. aureus stimulates bone resorption and osteoclast 
formation, and blockade of IL-1 or TNFǂ signalling completely abolishes this bone 
resorption activity. Neutralisation of TNFǂ and IL-6 fully abolishes SAM-stimulated 
osteoclastogenesis, with antagonism of IL-1 having only a partial effect. 
The effect of this SAM on osteoclast formation and stimulation of resorption does not 
require co-culture with osteoblasts, and does not require RANKL signaling[53]. S.epidermidis 
surface material can also induce bone resorption, by a mechanism that is strongly dependent 
on TNFǂ and, to a lesser extent, IL-1.Induction and release of these cytokines in response to 
pathogen-associated molecules involves two main classes of pattern recognition receptors 
(PRRs), the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). The production of 
TNFǂ and IL-6 by murine macrophages in response to S. aureus cell wall preparations is 
dependent on TLR2, and TLR2-deficient mice exhibit reduced survival of intravenous S. 
aureus infections compared to wild-type counterparts. Signalling through TLRs, in response 
to microbial ligands such as LPS, ‘primes’ the cell for IL-1ǃ production by inducing 
expression of the inactive, pro-form of the cytokine[54,55].IL-1ǃ is synthesised as a 31-kDa 
precursor molecule, and is processed to produce a 17-kDa active molecule by caspase-1. 
Caspase-1 activation, and subsequent processing and release of active IL-1ǃ involves 
assembly of a multiprotein complex known as the inflammasome. This complex consists of 
caspase-1, the adaptor protein ASC (apoptosis-associated speck-like protein containing a 
caspase recruitment domain (CARD)) and one of several NLR proteins, of which four are 
known to associate with inflammasomes[56].Each NLR responds to different activating 
signals, and although the exact recognition steps remain to be elucidated, reported stimuli 
include flagellin, anthrax lethal toxin, and muramyl dipeptide. A broad range of stimuli for 
NLRP3 (NLR family pyrin domain containing 3) have been reported, including S. aureus. 
Although NLRP3 and ASC are essential for IL-1ǃ secretion by murine macrophages in 
response to S. aureus, the stimulating signal is as yet unknown, and deletionof the ǂ-, ǃ- and 
Ǆ-toxins does not perturb production of the cytokine. The inflammasome is involved in cell 
death in response to bacterial invasion and although invasion of murine osteoblasts by S. 
aureus induces apoptosis, it is not established whether the inflammasome is involved. 
Signalling in response to IL-1 and TNF binding of to their respective receptors leads to 
eventual activation of the NFκB transcription factor and JNK (c-Jun N-terminal kinase) and 
p38 MAPK(mitogen-activated protein kinase) signaling[57,58]. Studies with knockout mice 
have shown that at least one of the p50 or p52 NFκB subunits is required for IL-1-induced 
osteoclast formation and resorptive activity, indicating that much of the osteoclastogenic 
activity of IL-1 is dependent on NFκB. TNFǂ binds to two receptors, TNF type I (TNF-R1) 
and type II (TNF-R2) receptor which differ in their signaling mechanisms although there is 
substantial signalling crosstalk between the two receptors. Interestingly, the S. aureus 
virulence factor protein A, in addition to possession of immunoglobulin G-binding activity, 
is able to bind to the TNF-R1 receptor and stimulates downstream signalling and 
inflammation. 
TNFǂ mediates the osteoclastogenic activity of RANKL. TNFǂ production by osteoclast 
progenitors is induced by RANKL and stimulates osteoclast differentiation in an autocrine 
manner. Signal transduction involves the activation of Janus family (JAK) tyrosine kinases 
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and subsequent phosphorylation and activation of STAT (signal transducers and activators 
of transcription) family transcription factors. IL-6 mediates bone resorption indirectly, and 
has no effect on isolated osteoclasts and IL-6 induction of osteoclastogenesis is dependent on 
the expression of the IL-6 receptor by osteoblasts, but not osteoclast progenitors. 
It is clear that these cytokines have a prominent role in modulating bone turnover, and 
perturbation of their levels can have profound effects on this process. Although some 
mechanistic details are currently lacking, there is strong evidence that S. aureus infection of 
bone initiates local and systemic production of TNFǂ, IL-1 and IL-6 via host PRRs. Elevated 
levels of these cytokines then shift the homeostatic balance of bone turnover, increasing 
osteoclast differentiation and bone resorption and iminishing osteoblast-mediated bone 
matrix production and mineralisation, thereby driving bone destruction. 
5.4 Staphylococcal invasion of bone cells 
In addition to staphylococcal induction of inflammatory mediators that modulate the 
actions of osteoblasts and osteoclasts, bacteria of this genus are involved in more direct 
interactions with bone cells. Invasion and persistence of S. aureus in ‘non-professional 
phagocytic’ host cells in vitro has been described for many different cell types, including 
epithelial cells, endothelial cells and keratinocytes[59]. In cell culture systems, S. aureus is 
able to invade cultured osteoblasts from murine, human and embryonic chick sources, and 
S. epidermidis is also able to invade and grow within cultured osteoblasts. Electron 
microscopy has demonstrated the presence of bacteria within osteoblasts and osteocytes of 
embryonic chicks following injection with S. aureus, indicating that internalisation by bone 
cells also occurs in vivo. Intracellular bacteria inside osteoblasts and osteocytes in a patient 
with recurrent, long-term osteomyelitis of the fibula have been visualised by light and 
electron microscopy. More recently Stoodley et al. [60]have demonstrated S. aureus biofilms 
in an infected total joint arthroplasty. Although not reported in this paper the authors also 
identified S. aureus within host cells (personal communications, Stoodley). Thus the 
suggestion that internalisation of S. aureus by bone cells in vivo provides a protective niche 
for the bacterium, where it is shielded from immune effector mechanisms and antibiotics, 
may help to explain persistent cases of osteomyelitis. However, the true importance of 
intracellular staphylococci in clinical osteomyelitis has yet to be established. 
S. aureus requires fibronectin-binding proteins (FnBPs) expressed on the surface of the 
bacterium to enable uptake by osteoblasts, and many other cell types. These proteins belong 
to a group of adhesions known as MSCRAMMs (microbial surface components recognising 
adhesive matrix molecules), which bind a range of extracellular matrix proteins including 
fibronectin, fibrinogen, collagen, elastin and bone sialoprotein. Mutants deficient in the two 
FnBPs, FnBPA and FnBPB invade host cells very poorly. Invasion is dependent on 
fibronectin binding by these proteins, and on the host cell integrin ǂ5ǃ1 receptor. S. aureus 
binds to fibronectin via FnBPs displayed on the bacterial surface, and fibronectin serves as a 
bridging molecule to the integrin ǂ5ǃ1 which acts as a “phagocytic”receptor. Alternative 
uptake mechanisms do exist in certain cell types, however, as S. aureus is still able to invade 
primary keratinocytes in the absence of FnBPs and uptake is not inhibited by blockade of 
integrin ǂ5ǃ1 binding to fibronectin. The mechanism of invasion also differs between S. 
aureus and S. epidermidis and the latter does not gain entry via the fibronectin-integrin ǂ5ǃ1 
mechanism[61]. 
The level of expression of the alternative sigma factor, σB, affects fnbA expression and the 
fibronectin binding ability of S. aureus strains and correlates with the level of internalization 
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of bacteria by osteoblasts suggesting that σB-mediated up-regulation of FnBP expression 
may facilitate invasion[62]. 
Integrin ͉5͊1-mediated uptake of S. aureus requires remodelling of the actin cytoskeleton. 
The integrin-linked kinase, ILK, provides a link between ͉5͊1 and the cytoskeleton, and 
interacts with the cytoplasmic domains of ͊ integrins and is subsequently activated. ILK 
activity is required for internalisation of S. aureus by epithelial cells. Recruitment of focal 
adhesion proteins, including the adaptor protein paxillin and the focal adhesion kinase, 
FAK, follows. Upon infection of HEK293T cells with S. aureus there is also recruitment of 
focal adhesion proteins, such as tensin, zyxin and vinculin to the site of bacterial attachment. 
FAK is recruited and tyrosine phosphorylated, and FAK-deficient cells are able to internalise 
S. aureus much less efficiently. Phosphorylation of downstream substrates of FAK, including 
cortactin, which is involved in actin cytoskeletal organisation, occurs during invasion, and 
interference with cortactin also reduces internalisation. So, signalling downstream of the 
integrin ͉5͊1 receptor, involving ILK and FAK, is important for S. aureus invasion, at least 
in certain cell types. 
Physical contact between S. aureus and osteoblasts induces host cell expression of tumour 
necrosis factor apoptosis inducing ligand (TRAIL) . TRAIL is a member of the TNF cytokine 
family, and binds to two death domain -containing receptors, TRAIL receptors 1 and 2, 
which once activated recruit the FADD (Fas-associated protein with death domain) adaptor 
protein which in turn activates caspases 8 and −10 and commits the cell to an apoptotic 
pathway[63]. TRAIL produced by S. aureus-infected osteoblasts induces caspase-8 activation 
and apoptosis in cultured osteoblasts. Uninfected osteoblasts cultured alongside infected 
cells also express TRAIL[64]. TRAIL can induce apoptosis in human osteoclasts via TRAIL 
receptor 2, and also inhibits osteoclast differentiation. It is therefore possible that apoptosis 
of bone cells infected with S. aureus, and potentially of neighbouring uninfected cells may 
contribute to bone loss in osteomyelitis . 
Growing experimental support indicates that staphylococcal invasion of osteoblasts, most 
likely via the FnBP-fibronectin-integrin ǂ5ǃ1 bridging mechanism in the case of S. aureus, 
may play a role in the pathogenesis of bone infections. This intracellular location may 
provide a protected environment for bacteria, aiding prolonged persistence by enabling 
evasion of antimicrobials and host immune mechanisms and possibly contributing to bone 
damage by inducing apoptosis of infected cells. 
5.5 Staphylococcal virulence determinants 
A number of animal models of bone implant infection, osteomyelitis and septic arthritis 
have been developed which have enabled the role of specific virulence factors in infections 
to be determined. As mentioned at the outset there are a number of routes of bone infection, 
i.e. haematogenous, contiguous and direct infection of bone, and models have been 
developed to mimic each of these routes of infection. This is important since the range of 
environments experienced by the bacterium differs for each route and hence the virulence 
factors that are involved in pathology may be different for each route of infection. The septic 
arthritis model developed by Tarkowski and colleagues in conjunction with defined 
isogenic mutants deficient in one or more virulence determinants, or with neutralising 
antibodies to virulence factors has proven to be particularly useful in elucidating the role of 
specific virulence determinants and host factors in bone infections. This model has shown 
that there is a plethora of virulence determinants involved in S. aureus septic arthritis. some 
of which are also involved in osteomyelitis. However, there is some controversy in this area 
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because whilst the murine septic arthritis model is well established and standardised a 
number of different models have been developed for osteomyelitis and the relevance of 
specific virulence factors to bone implant infections or osteomyelitis appears to be 
dependent on the particular model used. For example the collagen adhesin Cna has been 
shown to contribute to osteomyelitis by some workers but not by others and has been 
reported not to be important in orthopaedic device infections. The role of FnBPs has not 
been directly assessed in a model of osteomyelitis, but comparison of S. aureus strains with 
and without fibronectin-binding activity in a mouse osteomyelitis model suggests that 
fibronectin-binding strains may give rise to more severe bone infections. In the septic 
arthritis model, S. aureus fnbA fnbB mutants show no reduction in severity of arthritis, in 
contrast with clfA clfB mutants lacking the fibrinogen-binding clumping factors. However, 
the presence of the fnb genes results in greater weight loss and mortality, as well as higher 
serum levels of IL-6, indicating a role for FnBPs in the systemic inflammatory response. 
One area of research that has received surprisingly little attention is that of the direct action 
of virulence factors on bone and bone cells. Work in our own laboratory has shown that 
S.aureus and S. epidermidis produce surface-associated proteins that can stimulate bone 
breakdown in an in vitro assay. These surface-associated proteins and capsular material 
appear to promote the formation and activation of the boneresorbing osteoclast. 
Interestingly, a proportion of the population have antibodies that can block the action of the 
S. aureus proteins and prevent bonebreakdown. The identity of the protein(s) in these 
mixtures which cause bone destruction has not been elucidated.   
5.6 Small colony variants 
Variant forms of S. aureus, known as small colony variants (SCVs), are associated with 
infections of bone and joint that may be particularly persistent, recurrent and refractory to 
antibiotic treatment[65]. These bacteria are mutant forms of Staphylococcus that may have an 
adaptive advantage enabling persistent bone colonisation. 
SCV forms of coagulase-negative staphylococci, including S. epidermidis, S. lugdunensis and 
S. capitis have also been isolated from a range of infections. The SCV phenotype is 
characterised by slow growth, with colonies around 10-fold smaller than wild-type forms, 
often with decreased pigmentation, increased aminoglycoside resistance and some reports 
of reduced haemolytic activity[66]. The nature of these phenotypes can cause difficulty in 
detection and identification of the bacteria, and may contribute to an underestimation of the 
clinical prevalence of SCVs [67]. These phenotypes usually result from auxotrophy for 
hemin, menadione or thymidine and can be reversed by supplementation with these 
molecules. Mutations in the hemB and menD genes produce hemin and menadione 
auxotrophic strains with typical SCV phenotypes, and give rise to disruption of electron 
transport which is the basis of the growth deficiency, increased minoglycoside resistance 
and other phenotypes. SCVs can be selected for with gentamicin in vitro, and there is 
evidence that antibiotic therapy, in particular use of gentamicin beads, which are used in 
addition to debridement and systemic antibiotic therapy for osteomyelitis may select for 
SCVs in clinical situations. In a cohort of fourteen patients with confirmed S. aureus 
osteomyelitis, SCVs were isolated only from those four that had received gentamicin bead 
therapy, with the remaining ten patients harbouring normal S. aureus strains. Of the four 
SCVs, three were auxotrophic for hemin, and one for menadione. Only the patients 
harbouring SCVs had recurrent infections, although only patients whose gentamicin bead 
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therapy had failed were included in the study. SCVs have also been isolated from cases of 
infection of hip prostheses, and intracellular bacteria within host fibroblasts were identified 
in one of the five instances. 
Clinically isolated SCVs with hemin auxotrophy, and defined hemB mutants, show 
enhanced intracellular persistence in a range of human cell types. The basis of this 
persistence is not established but may involve a number of possible mechanisms. S. aureus 
hemB mutants exhibit enhanced binding to fibrinogen and fibronectin, and transcribe and 
display more ClfA and FnBP on their surface, which may increase attachment and uptake by 
host cells. Transcriptional profiling of clinical and defined mutant SCVs reveals increased 
transcription of genes regulated by σB, including adhesin genes, and down-regulation of 
exoprotein and toxin genes. The effect of increased σB activity on MSCRAMM expression 
has been shown to correlate well with osteoblast invasion, adding weight to the argument 
that σB-mediated upregulation of adhesins increases host cell invasion, at least in vitro, and 
that increased invasion by SCVs may be partially dependent on this mechanism. It has been 
argued that reduced production of toxins, particularly haemolysins, by SCVs also 
contributes to intracellular persistence by reducing the cytotoxic effect on host cells. 
In a murine septic arthritis model, a defined stable hemB mutant, exhibiting the SCV 
phenotype, elicited more frequent and severe arthritis than the parental strain despite a 
reduced bacterial load in the kidney and joints. It has been argued that SCVs are therefore 
more virulent on a‘per organism’ basis and that enhanced protease production by hemB 
mutants may partially explain this. It may be that in clinical infections relatively small 
numbers of SCVs with enhanced virulence survive within tissues, possibly intracellularly, 
for extended periods and cause persistent infections. Clinically isolated SCVs are able to 
revert to the parent phenotype, although to what extent this may play a role in infections, 
and whether S. aureus may ‘switch’ between states in different in vivo situations is currently 
unclear. 
6. Diagnostic approach 
It is important to accurately diagnose prosthetic-joint–associated infection because its 
management differs from that of other causes of arthroplasty failure. Although there is no 
universally accepted definition of this type of infection, the criteria listed in Table 3 have 
been applied in a number of studies. 
 
 
 
Table 3. Criteria for the Diagnosis of a Prosthetic-Joint Infection. 
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Establishing the presence of acute infection or, in the presence of a draining sinus, chronic 
infection, is uncomplicated. In these situations, testing may be limited to that needed to 
establish the microbiologic diagnosis. Chronic infection manifested as localized joint pain 
alone poses more diagnostic difficulty, warranting additional testing. The criteria for 
interpreting laboratory and imaging findings in patients with a prosthetic joint are distinct 
from those applied in patients with a native joint. In addition to establishing the diagnosis, the 
identification of the involved organism or organisms and their antimicrobial susceptibility (i.e., 
on the basis of cultures of synovial fluid, periprosthetic tissue, the implant, or a combination of 
such cultures) is important in order to guide antimicrobial therapy. 
C-Reactive Protein—In the absence of underlying inflammatory conditions, CRP 
measurement is the most useful preoperative blood test for detecting infection associated 
with a prosthetic joint. CRP testing has a sensitivity of 73 to 91% and a specificity of 81 to 
86% for the diagnosis of prosthetic-knee infection with the use of a cutoff point of 13.5 mg 
per liter or more[68,69]. It has a sensitivity of 95% and a specificity of 62% for the diagnosis 
of prosthetichip infection with the use of a cutoff point of more than 5 mg per liter[70]. 
Although the CRP level and erythrocyte sedimentation rate are elevated after 
uncomplicated arthroplasty, the CRP level returns to the preoperative level within 2 
months, whereas the erythrocyte edimentation rate may remain elevated for several months. 
A normal CRP level generally indicates an absence of infection, although false negative 
results may occur in patients who have been treated with antimicrobial agents or who have 
infection that is caused by low-virulenceorganisms such as P. acnes. Elevations in the 
peripheral -blood leukocyte count and levels of procalcitonin have low sensitivity for 
detecting infection. 
Imaging—Plain radiography has low sensitivity and low specificity for detecting infection 
associated with a prosthetic joint[71]. Periprosthetic radiolucency, osteolysis, migration, or 
all of these features may be present on radiographs in patients with either infection or 
aseptic loosening of the prosthesis. Diagnostic studies with the use of computed 
tomography (CT) or magnetic resonance imaging (MRI) are hampered by artifacts produced 
by prostheses, although implants that are not ferromagnetic (i.e., titanium or tantalum) are 
associated with minimal MRI artifacts, and MRI scans of such implants provide good 
resolution for detecting soft-tissue abnormalities. Bone scans obtained after the 
administration of technetium-99m –labeled methylene diphosphonate are sensitive for 
detecting failed implants but nonspecific for detecting infection, and they may remain 
abnormal for more than a year after implantation. 
Some studies suggest that combined bone and gallium-67 scans are more specific than bone 
scans alone. However, labeled-leukocyte imaging (e.g., leukocytes labeled with indium-111) 
combined with bone marrow imaging with the use of technetium -99m–labeled sulfur 
colloid is more accurate than bone imaging alone, combined bone and gallium-67 imaging, 
or labeledleukocyte and bone imaging when compared head to head, and it is considered 
the imaging test of choice when imaging is required[71]. 18F-fluorodeoxyglucose positron-
emission tomography (PET) has a sensitivity of 82% and a specificity of 87% for the 
detection of prosthetic-knee or prosthetic-hip infection, on the basis of pooled data from 
several studies, but it is not widely available[72]. Newer imaging strategies such as 
scintigraphy with antigranulocyte monoclonal antibodies and hybrid imaging (e.g., 
combined PET and CT) (see Fig. 3)are under investigation. 
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Fig. 3. Bone Scan, Labeled-Leukocyte Scan and Positron Emission Tomography/Computed 
Tomography Scan from a Patient with Prosthetic Joint Infection. 
In Panel A, an anterior bone scan obtained after the administration of technetium-99m–
labeled methylene diphosphonate shows diffusely increased activity around the femoral 
component of a left hip replacement, with foci of increased activity at the tip of the femoral 
component and around the tibia. In Panel B, a labeled leukocyte scan obtained after the 
administration of indium-111–labeled leukocytes shows accumulation of labeled leukocytes 
that is spatially congruent with the bone scan image shown in Panel A. In Panel C, 18F-
fluoro-2-deoxyglucose positron emission tomography/computed tomography coronal and 
sagittal images show increased activity around the bone-prosthesis interface. 
Staphylococcus epidermidis and Finegoldia magna were isolated from the periprosthetic 
tissue. (Images courtesy of Carmen Vigil, M.D., and Jose Angel Richter, M.D., Department of 
Nuclear Medicine, University Hospital of Navarre, Pamplona, Spain.) 
Synovial-Fluid Studies—If there is uncertainty about the diagnosis, the most useful 
preoperative diagnostic test is aspiration of joint synovial fluid for a total and differential 
cell count and culture. Aspiration should not be performed through overlying cellulitis. Hip 
aspiration may require imaging guidance. A synovial-fluid leukocyte count of more than 
1.7×103 per cubic millimeter or a differential count with more than 65% neutrophils is 
consistent with prosthetic-knee infection. A synovial-fluid leukocyte count of more than 
4.2×103 per cubic millimeter or more than 80% neutrophils is consistent with prosthetic-hip 
infection[73]. The leukocyte count cutoffs are dramatically lower than those used to 
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diagnose native-joint infection. Synovial-fluid culture has a sensitivity of 56 to 75% and a 
specificity of 95 to 100%, and to achieve optimal sensitivity and specificity, it should be 
performed by means of inoculation into a blood-culture bottle. If an organism of 
questionable clinical significance is isolated, repeat synovial-fluid aspiration for culture 
should be considered. Previous antimicrobial treatment reduces the sensitivity. 
Histopathological Examination of Periprosthetic Tissue—In patients in whom the 
diagnosis of prosthetic-joint–associated infection has not been established preoperatively, an 
intraoperative frozen section may be obtained to look for evidence of acute inflammation. In 
studies that used a polymorphonuclear-cell count ranging from more than 5 to 10 or more 
cells per high-power field as a positive test, sensitivity for infection ranged from 50 to 93% 
and specificity ranged from 77 to 100%; the rate of interobserver agreement was 86%. 
Intraoperative Microbiologic Testing—Identification of the pathogen or pathogens is critical 
for choosing the antimicrobial regimen; if microbiologic testing has not been done 
preoperatively, specimens should be collected for microbiologic study at the time of surgery. 
Antimicrobial therapy should be discontinued at least 2 weeks before surgery, and 
perioperative antimicrobial coverage should be deferred until culture specimens have been 
collected. Cultures of sinus tract exudates should be avoided; these are often positive because 
of microbial skin colonization and correlate poorly with cultures of surgical specimens. 
If periprosthetic tissue is obtained, collection of multiple periprosthetic-tissue specimens for 
aerobic and anaerobic bacterial culture is imperative because of the poor sensitivity of a 
single culture and to distinguish contaminants from pathogens. A study that used 
mathematical modeling to estimate yield based on the number of cultures concluded that to 
maximize accuracy, five or six specimens should be submitted for culture, and two or three 
culturepositive samples would be considered to be diagnostic. 
Periprosthetic-tissue cultures may be falsely negative because of previous antimicrobial 
therapy, leaching of antimicrobial agents from antimicrobial -impregnated cement, biofilm 
growth on the surface of the prosthesis (but not in the surrounding tissue), a low number of 
organisms in tissue, an inappropriate culture medium, an inadequate culture incubation 
time, or a prolonged time to transport the specimen to the laboratory. Because of poor 
sensitivity, neither intraoperative swab cultures nor Gram’s staining of the periprosthetic 
tissue is recommended. Fungal cultures, mycobacterial cultures, or both may be considered 
(e.g., if bacterial cultures are negative in a patient with apparent infection), but they are not 
routinely recommended. 
Microorganisms form a biofilm on the prosthesis; therefore, if the prosthesis is removed, 
obtaining a sample from its surface is useful for microbiologic diagnosis. The implant is 
removed and transported to the laboratory in a sterile jar. After the addition of Ringer’s 
solution, the container is vortexed and sonicated (frequency, 40 kHz; power density, 0.22 W 
per square centimeter) for 5 minutes in a bath sonicator, and the resultant fluid is cultured. 
This technique is more sensitive than and as specific as multiple periprosthetic-tissue 
cultures for diagnosing infection of a prosthetic hip, knee, or shoulder, provided that an 
appropriate cutoff for significant results is applied. This technique is particularly helpful in 
patients who have received previous antimicrobial therapy. In a study involving patients 
receiving antimicrobial agents within 2 weeks before surgery, the sensitivity of 
periprosthetic-tissue culture was 45%, whereas the sensitivity of sonicate-fluid culture was 
75% (P<0.001). Sonication in bags is not recommended because of the potential for 
contamination.  
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6.1 Treatment 
The goal of treatment is to cure the infection, prevent its recurrence, and ensure a pain-free, 
functional joint. This goal can best be achieved by a multidisciplinary team consisting of an 
orthopedic surgeon, an infectious-disease specialist, and a clinical microbiologist. On the basis 
of clinical experience, the use of antimicrobial agents alone, without surgical intervention, 
ultimately fails in most cases. Careful surgical débridement is critical. A general approach to 
surgical management is outlined in Figure 4; different centers and surgeons may use slightly 
different strategies. Chronic infections require resection arthroplasty either as a onstage 
exchange (i.e., removal of the infected prosthesis and reimplantation of a new prosthesis 
during the same surgical procedure) or a two-stage exchange (i.e., removal of the infected 
prosthesis and administration of systemic antimicrobial agents with subsequent implantation 
of a new prosthesis, usually between 6 weeks and 3 months after the first stage). Case series 
have suggested improved outcomes with a one-stage exchange when polymethylmethacrylate 
impregnated with one or more antimicrobial agents is used. A spacer impregnated with one or 
more antimicrobial agents may be used to maintain the leg at its correct length and to control 
infection during the prosthesis-free interval of a two-stage exchange. In a randomized trial 
involving patients with infection associated with hip arthroplasty, the use of a 
vancomycinloaded spacer (as compared with no spacer) resulted in a lower rate of recurrent 
infection (11% vs. 33%, P = 0.002)[74]. 
Patients who have had symptoms of infection for fewer than 3 weeks, who present with 
infection within 3 months after implantation or who have hematogenous infection, and who 
have a well-fixed, functioning prosthesis, without a sinus tract, and with an appropriate 
microbiologic diagnosis (Fig. 4) may be candidates for débridement and retention of the 
prosthesis. The addition of rifampin is recommended in cases of rifampin-susceptible 
staphylococcal infection. In a small, randomized trial comparing different antibiotic 
regimens in patients with staphylococcal infection of prosthetic knees or hips or 
osteosynthetic implants, salvage of the implant was successful in all 12 patients treated for 3 
to 6 months with rifampin and ciprofloxacin, as compared with successful salvage in 7 of 12 
patients treated with ciprofloxacin alone for 3 to 6 months (P = 0.02). 
When unacceptable joint function is anticipated after surgery or the infection has been 
refractory to multiple surgical attempts at cure, resection arthroplasty with creation of a 
pseudarthrosis for hips (Girdlestone resection) or arthrodesis for knees may be considered. 
If the patient is not a candidate for surgery, antimicrobial suppression may be attempted; 
this approach is unlikely to cure infection, so the use of antimicrobial agents is often 
continued indefinitely. 
In brief, information about antimicrobial susceptibility should be used to confirm the 
activity of any antimicrobial agent used for therapy. Data from randomized trials on the 
optimal duration of treatment are lacking. The therapeutic approach has to be selected in 
accordance with the mode of infection (NJI, PJI, RA), the expected or found pathogens, and 
their resistance. It should be remembered that the slowed growth of bacteria in a biofilm on 
surfaces of joint prosthesis may additionally reinforces antibiotic resistance. Responsible for 
such an increase against antibacterial substances are changes in cell wall synthesis, which 
limits the effect of beta-lactam antibiotics and glycopeptides, and the occurrence of bacterial 
variants with modifications of other metabolic activities, with implications for the action of 
quinolones, aminoglycosides, and tetracyclines. In principle, the spectrum of available 
antibiotics is limited by the specific pharmacokinetic requirements in the treatment of joint 
infections. This applies particularly to chronic infections and prosthesis infections.  
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Fig. 4. Algorithm for the Treatment of Infection Associated with a Prosthetic joint 
www.intechopen.com
 
Recent Advances in Arthroplasty 
 
478 
 
(all given dosages are for healthy adults of 70 kg with normal liver and kidney function) 
Table 4. Antibiotics for therapy of infectious arthritis 
Lysostaphin is a 27 kDa endopeptidase that was first isolated from a culture of 
Staphylococcus simulans by Schindler & Schuhardt. The enzyme kills the organism by 
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hydrolysing a pentaglycine cross-bridge structure unique to the staphylococcal cell wall. As 
the cell wall cross-bridges of S. aureus are composed of a high proportion of pentaglycine, 
both proliferating and quiescent S. aureus cells are highly sensitive to lysostaphin. 
Lysostaphin kills meticillin-susceptible S. aureus (MSSA) and MRSA equally well and has 
been demonstrated to be a potent therapeutic agent for S. aureus infections in various 
animal studies. In the USA, two therapeutic products formulated with recombinant 
lysostaphin for topical use have entered clinical studies. And recombinant lysostaphin is 
expected to be a potential alternative therapy for S. aureus infection[78]. 
For an overview of common substances and therapeutic regimes, see Table 4. 
In patients undergoing débridement with retention of the prosthesis, 3-month courses of 
treatment for infection associated with hip prostheses and 6-month courses for infection 
associated with knee prostheses are often used. Oral therapy can be used if the agent has 
good oral bioavailability (e.g., quinolones, rimethoprim– sulfamethoxazole, and 
tetracyclines). In patients undergoing a two-stage exchange, systemic antimicrobial therapy 
is often administered for 4 to 6 weeks. Commercially available, preblended, 
polymethylmethacrylate impregnated with an antimicrobial agent is indicated for use in the 
second stage of a two-stage revision after elimination of active infection. Although it is not 
standard clinical practice, two studies involving a long period between the initial and 
second stages suggest that when a polymethylmethacrylate spacer impregnated with one or 
more antimicrobial agents or impregnated beads are used, the administration of systemic 
antimicrobial therapy for 2 weeks may be sufficient or systemic therapy may even be 
unnecessary[75,76].  
6.2 Prophylaxis 
In addition to good aseptic technique and procedures in the operating room, the 
administration of intravenous antimicrobial agents immediately before surgery minimizes 
the risk of infection. Cefazolin at a dose of 1 g (2 g if the patient weighs  80 kg) every 8 
hours or cefuroxime at a dose of 1.5 g, followed by 750 mg every 8 hours is recommended 
routinely; vancomycin at a dose of 15 mg per kilogram every 12 hours (assuming normal 
renal function) is used in patients with a ͊-lactam allergy or MRSA colonization. 
Prophylaxis should begin within 60 minutes before surgical incision (within 120 minutes if 
vancomycin is used) and should be completed within 24 hours after the end of surgery. The 
entire antimicrobial dose should be infused before inflation of a tourniquet[77]. 
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